What is the optimal management for a patient with hypertensive heart failure presenting with hypertension and congestion?

Hypertensive Heart Failure Treatment

For hypertensive heart failure with congestion, immediately initiate IV loop diuretics combined with SGLT-2 inhibitors and rapidly up-titrate guideline-directed medical therapy (GDMT) rather than relying on diuretics alone, as this approach addresses both immediate decongestion and the underlying pathophysiology that drives mortality and rehospitalization. 1, 2

Immediate Management of Acute Congestion

Initial Diuretic Strategy Based on Blood Pressure

• If SBP >110 mmHg: Start IV furosemide 20-40 mg (if diuretic-naïve) or 1-2 times the daily oral dose IV (if on chronic diuretics), combined with IV nitrates 2
• If SBP 90-110 mmHg: Use standard-dose IV loop diuretics with cautious nitrate use and blood pressure monitoring every 5-15 minutes 2
• If SBP <90 mmHg: Use lower initial diuretic doses and avoid vasodilators entirely 2

Early Response Assessment (Within 2 Hours)

• Measure spot urinary sodium with target ≥50-70 mmol/L 3, 2
• Monitor urine output with target ≥100-150 mL/hour 2
• If targets not met: Add acetazolamide 500 mg IV once daily or thiazide diuretics (metolazone or hydrochlorothiazide) for sequential nephron blockade 2

Critical Paradigm Shift: Beyond Diuretics

The traditional "diuretic-centric" approach that focuses solely on fluid removal without optimizing neurohormonal blockade only addresses symptoms and fails to prevent subsequent decompensations or death. 3, 1

Immediate Addition of SGLT-2 Inhibitors

• Initiate empagliflozin or dapagliflozin immediately after initial stabilization during hospitalization 1, 2
• SGLT-2 inhibitors address sodium avidity at the nephron level while providing mortality and hospitalization benefits independent of background therapy 3, 1
• These agents require no dose adjustment, do not affect blood pressure or heart rate, and show benefits within weeks of initiation 3

Comprehensive GDMT for Hypertensive Heart Failure

Core Medications (Class I Recommendations)

All patients with hypertensive heart failure should receive the following four-pillar therapy: 3

1. ACE inhibitors (or ARBs if ACE inhibitor intolerant, or sacubitril/valsartan) 3
2. Beta-blockers (evidence-based agents: carvedilol, metoprolol succinate, bisoprolol) 3
3. Mineralocorticoid receptor antagonists (spironolactone or eplerenone) 3
4. SGLT-2 inhibitors (empagliflozin or dapagliflozin) 3, 1

Rapid Up-Titration Strategy

• Initiate all core medications simultaneously rather than sequential step-by-step titration 3
• Once excess fluid is removed, shift focus to rapid up-titration of GDMT rather than increasing diuretic doses 1
• Dose modifications should be performed considering blood pressure, heart rate, presence of congestion, and kidney function 3

Blood Pressure Management in Heart Failure

Target Blood Pressure

• Standard HF treatment typically lowers systolic blood pressure to 110-130 mmHg 3
• No specific BP target is firmly established for patients with established HF, but treatment of HF itself usually normalizes BP 3
• After optimization of HF treatment, if BP remains uncontrolled, add dihydropyridine calcium channel blockers (amlodipine or felodipine) only after other medications have failed 3

Additional Agents for Persistent Hypertension

• For Black patients with NYHA class III-IV symptoms: Add hydralazine/isosorbide dinitrate to ACE inhibitor/ARB and beta-blocker (Class I recommendation) 3
• For non-Black patients: Hydralazine/isosorbide may be beneficial for BP control (Class IIa recommendation) 3
• Thiazide or thiazide-like diuretics can be useful for BP control and mild volume overload, though loop diuretics are preferred for congestion 3

Critical Drugs to Avoid

Never use the following in hypertensive heart failure: 3

• Nondihydropyridine calcium channel blockers (verapamil, diltiazem) - Class III: Harm 3
• Moxonidine - Class III: Harm 3
• Alpha-adrenergic blockers (doxazosin) should be avoided unless all other options exhausted 3

Behavioral Modifications (Class I Recommendation)

• Sodium restriction (typically <2-3 grams daily) 3
• Closely monitored exercise program 3
• Weight reduction in overweight/obese patients 3
• Moderation of alcohol intake 3

Monitoring and Discharge Criteria

Do Not Discharge With Residual Congestion

• Residual congestion at discharge is the strongest predictor of early rehospitalization and death 1
• Physical signs and symptoms only detect moderate to high levels of congestion and are late manifestations 1
• A decrease >30% in natriuretic peptides at day 5 predicts better outcomes 1

Accept Minor Creatinine Increases

• Minor creatinine increases during decongestion often represent beneficial hemodynamic changes rather than true kidney injury 1
• Continue decongestion if patient is clinically improving despite mild creatinine elevation 1

Common Pitfalls to Avoid

• Do not delay diuretic administration: Door-to-diuretic time should not exceed 60 minutes 2
• Do not discharge patients on the same or higher diuretic doses without adequate GDMT up-titration: This only targets symptoms and does not protect against subsequent decompensations 1
• Do not use vasodilators in patients with SBP <90 mmHg: They may reduce central organ perfusion 2
• Do not rely solely on escalating diuretics: This approach fails to address underlying pathophysiology and leads to neurohormonal activation, diuretic resistance, and recurrent decompensations 3, 1, 2